Stockreport

Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative C...

TAKEDA PHARMA  (TKPYY) 
NASDAQ:AMEX Investor Relations: takeda.com/investors
PDF Additional subgroup analysis shows subcutaneous formulation of vedolizumab achieves significantly higher clinical remission rates to placebo in anti-TNFa [Read more]